Our partnerships
Cancer Research Horizons partners across the fields of academia, industry, drug discovery and investors.
Dr Guldberg funded by the Danish Cancer Society has invented a useful, patent protected high speed methylation detection assay. It is hoped that it will lead the way to the use on a routine basis of diagnostic tests based on DNA methylation.
Epigenomics will develop and commercialise this novel methylation detection assay. Most recent research has shown that DNA methylation patterns correlate with various disease states and in particular with cancer. Identification of the aberrantly methylated genes will certainly lead to the development of novel diagnostics and therapeutics.
CRV provides commercialisation and intellectual property management services to cancer research institutes world-wide. CRV’s goal is to bridge the gap between exciting new research, in this case funded by the DCS at the Institute of Cancer Biology and its timely development by the best suited commercial partner.
